Navigation Links
CHPA Responds to Kentucky Senate Judiciary Passage of Senate Bill 3
Date:3/1/2012

WASHINGTON, March 1, 2012 /PRNewswire/ -- The Consumer Healthcare Products Association (CHPA) released the following statement after the Kentucky Senate Judiciary Committee passed Senate Bill 3, legislation that would impose significant restrictions on safe and effective medicines containing pseudoephedrine (PSE), such as Advil Cold & Sinus, Allegra-D, Claritin-D, Mucinex D, and Sudafed.  SB 3 would limit the amount of PSE consumers can buy to 15 grams a year and 3.6 grams a month. The measure now moves to the full Senate for consideration.  

"Severe restrictions on cold and allergy medicines containing pseudoephedrine will prevent chronic allergy suffers and many Kentucky families from accessing affordable, quality healthcare they rely upon," said Scott Melville, president and chief executive officer of the CHPA. "For thousands of Kentuckians—especially those who suffer from seasonal allergy symptoms—there's absolutely no difference between a prescription mandate and Senate Bill 3, especially given the fact that the Commonwealth of Kentucky has one of the longest allergy seasons in the country. The significant gram limit called for in SB 3 would lead to involuntary time off work, lost wages and increased health expenses for many responsible Kentucky families and workers."

"Kentucky Senators made the right decision when they shut the door on SB 50 last week. We are hopeful that the Kentucky Senate will listen to their constituents and enact anti-meth policies that target criminals without burdening responsible workers and families with additional barriers to these legal medicines."

www.chpa-info.org

CHPA is the 131-year-old-trade association representing U.S. manufacturers and distributors of over-the-counter medicines and dietary supplements.


'/>"/>
SOURCE Consumer Healthcare Products Association
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. CHPA Responds to Prescription Mandate Cost Implications Outlined in Oklahoma Economic Impact Study
2. Questcor Pharmaceuticals Responds to Questions From Investor Blog
3. AVMA Responds to Federal Order Limiting Use of Antibiotics In Food Animals
4. Ampio Responds to Recent Publications by Anonymous Short Sellers
5. Nationwide Coalition Responds to Express Scripts CEO Statement: "I Cant Stop Certain Pharmacies From Going Out of Business"
6. China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group
7. International Academy of Compounding Pharmacists (IACP) Responds to FDAs Appeal of the U.S. District Court Ruling on Pharmacy Compounding
8. Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimers Patent Application
9. NeuroSigma Responds to Substantial Interest Generated by NPR Story on Promising Epilepsy Clinical Trial
10. Cellestis Responds to World Health Organization Guidance on Use of Blood Tests for Active Tuberculosis
11. Takeda Responds to U.S. Food and Drug Administration Update to Safety Review of ACTOS (pioglitazone HCl)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... CITY, Calif. , March 28, 2017 /PRNewswire/ ... company focused on the development and commercialization of ... pain, announced that the European Medicines Agency (EMA) ... sublingual tablet, 30 mcg) Marketing Authorisation Application (MAA) ... of the MAA is underway. The MAA for ...
(Date:3/28/2017)... Mass. , March 28, 2017 ... company developing innovative therapeutics that address significant unmet ... a patent from the Japan Patent Office (JPO) ... connective tissue growth factor (CTGF) for the treatment ... limited to skin fibrosis and proliferative retinopathy (Japanese ...
(Date:3/28/2017)... , March 28, 2017 The ... reach USD 8.0 billion by 2025, according to a ... incidence of infectious diseases and cancer is expected to ... disease diagnosis over the coming years. In addition, higher ... autologous and allogenic stem cell therapy, due to adverse ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... Revolution for Truth has organized ... protect parental rights and civil liberties, and to restore transparency within government agencies ... coincides with a press conference taking place Friday morning calling on President Trump ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... and services, is proud to announce it has joined the National Association for ... the interests of chronically ill, disabled, and dying Americans of all ages and ...
(Date:3/28/2017)... ... 2017 , ... Z-Medica, LLC, a leading developer and marketer ... will acquire QuikClot® Bleeding Control Kits® (BCK) to equip up to 1,000 schools ... by the American College of Surgeons, U.S. Department of Defense, Department of Homeland ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... instruments are critical to ensuring high-quality results and maintaining GMP and USP compliance. ... Laboratory Instruments in accordance with GMP requirements " these requirements are explained. ...
(Date:3/28/2017)... ... 2017 , ... With less than 10,000 dermatologists in the United States and ... limited while the desire to conquer breakouts and eliminate skincare stress is widespread. ... online, today released its inaugural survey on the State of Acne in America. ...
Breaking Medicine News(10 mins):